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A B S T R A C T   
Introduction and importance: Bariatric surgery is an evolving surgical field with increasing cases per year, as 
obesity is prevalent, especially in developed countries. Complication diagnosis and management can be chal-
lenging. Marginal ulcers and anastomosis perforation are rare, but their incidence is likely underestimated. 
Case presentation: To the best of our knowledge, we present the first case with a two and a half years history of 
recurrent ischemia, marginal ulcers, and recurrent perforation after laparoscopic omega loop gastric bypass, 
most likely due to an abuse of an over-the-counter (OTC) sympathomimetic nasal spray. The complications 
(Clavien-Dindo classification IIIb) caused the necessity of recurrent hospitalizations and diagnostic interventions 
and an open conversion into Roux-Y gastric bypass in a damage control manner. 
Clinical discussion and conclusion: Conclusively, we advocate evaluating drug abuse, including OTC medications 
that patients might not report on a daily-based medical history, as an etiology for marginal ulcers and anasto-
mosis perforation, especially in late and recurrent cases.   
1. Introduction 
Obesity (BMI ≥ 30 kg/m2) with related comorbidities is gradually 
becoming one of the most frequent diseases, with a prevalence of 13.2% 
globally and 25.3% in Europe in 2016 [1,2]. Since the introduction of 
surgical bariatric interventions, different procedures have evolved, and 
the number of modalities is increasing. According to the most recent 
survey of the International Federation for the Surgery of Obesity and 
Metabolic Disorders (IFSO) in 2018, 696,191 surgical and endoluminal 
procedures were performed globally, with 55.4% being sleeve- 
gastrectomy (SG) and 29.3% Roux-en-Y gastric bypass (RYGB) as the 
two most frequently used procedures [3]. A Cochrane review (2014) 
could not find a consistent superiority between laparoscopic RYGB 
(LRYGB), open RYGB, and laparoscopic SG (LSG) about complications 
and mortality [4]. However, a study published in 2019 including 
>250,000 patients with significantly lower postoperative complication 
rates in LSG than in LRYGB was found [5]. Complications include 
bleeding, hemorrhage, staple line leaks, strictures, bile reflux, intus-
susception, and ulcer or perforation at the anastomosis [5–9]. 
To our knowledge, no data is available so far on recurrent ischemia 
and gastro-jejunal anastomosis (GJA) perforation after laparoscopic 
omega-loop gastric bypass (LOL-GB) or RYGB - caused by 
sympathomimetic nasal spray abuse. Given the lack of literature, we 
present the following patient with GJA ischemia after bariatric surgery, 
most likely caused by xylometazoline-based nasal spray abuse. 
2. Presentation of case 
A 53-year-old Caucasian female patient received LSG due to severe 
(WHO class III) obesity with a BMI of 48.6 kg/m2 at the University 
Hospital of Bern in Switzerland by a Swiss Society for the Study of 
Morbid Obesity and Metabolic Disorders certified surgeon. Relevant 
comorbidities were hypertension, dyslipidemia, severe obstructive sleep 
apnea, chronic obstructive pulmonary disease GOLD II (smoking [cu-
mulative 40 packyears]), as well as bilateral symptomatic arthrosis of 
the lower extremities and spine. Patients Timetable, weight progression, 
and interventions are displayed in Table 1. 
Two years after initial surgery, a weight loss of 37.5 kg was docu-
mented (BMI 34.1 kg/m2). At two and a half years after LSG, due to a 
weight regain of 10.5 kg (BMI 38.2 kg/m2), LOL-GB was performed, and 
the patient was uneventfully discharged on day three. 
About two months after laparoscopic omega-loop, the patient pre-
sented to our emergency department (ED) with an acute onset of 
abdominal pain with computed tomography (CT) signs suggesting a 
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possible intestinal perforation (perigastric, perisplenic, and perihepatic 
free air and liquid) (Fig. 1). Emergency diagnostic laparoscopy was 
performed. A biopsy of the 10 by 10 mm sized perforation of the GJA 
after LOL-GB was performed. The defect was closed using V-Loc© 3.0 
continuous suture and covered with an omentum patch. Antibiotic 
therapy was established using piperacillin/tazobactam intravenously for 
nine days followed by a total of eight days of oral clavulanic acid/ 
amoxicillin accompanied by proton pump inhibitors (PPI) therapy using 
pantoprazole 40 mg twice daily. Histopathological results yielded 
fibrinogen leukocyte exudate but no signs for malignancy. On the 
eleventh day after surgery, the patient was discharged home. 
About one month after discharge, the patient presented to our ED 
with diarrhea for three days, accompanied by one episode of melena and 
hematemesis. CT demonstrated thickened gastric wall without signs of 
perforation. After 24 h of uneventful monitoring, the patient was dis-
charged. The further diagnostic was planned and performed in the 
outpatient clinic using gastroscopy, which demonstrated a large ulcer of 
the GJA and a smaller ulcer distally to the anastomosis. The highly dosed 
regimen of proton pump inhibitors (PPI) was established for four weeks. 
Regular check-ups in our outpatient clinic followed, where rarely 
intermittent epigastric patient and diarrhea were reported. Re- 
gastroscopy (no ulcer, bile reflux and suspected discrete reactive gas-
tropathy; histopathologically discrete chronic type c gastritis) and a 
lactulose breath test (H2-concentration 60 min >20 ppm and CH4- 
concentration always <8 ppm) were performed, and an antibiotic 
(Gentamycin) decontamination for suspected small intestinal bacterial 
overgrowth (SIBO) was prescribed. At following check-ups patient's 
complaints improved but re-occurred with intermittent abdominal pain, 
vomiting, diarrhea, and constipation. Complaints slightly decreased by 
the use of laxatives. The lactulose breath test was repeated after seven 
months (H2-concentration 90 min >20 ppm and CH4-concentration 
150 min >8 ppm), suggesting possible SIBO. PPI therapy was 
continued (pantoprazole 20 mg three times daily). 
Thirty months after LOL-GB, the patient presented to our ED with 
persisting abdominal pain for three days, recurrent vomiting, and 
diarrhea. The patient was hemodynamically stable, had a quick sepsis- 
related organ failure assessment score (qSOFA) of 0/3 points, and had 
a flat abdomen. Laboratory testing showed an elevated CRP 39 mg/L 
and normal lactate (1.20 mmol/L). CT scan showed free air and liquids 
in the epigastrium with a thickened wall of the omega loop but no signs 
of relevant vascular pathology (Fig. 1). Empirical antibiotic therapy 
with piperacillin/tazobactam was established. Explorative laparotomy 
presented four-quadrant peritonitis with a perforation of the anterior 
wall of the GJA. The omega loop was heavily inflamed. After adhesiol-
ysis, the GJA was resected, followed by peritoneal lavage and closure of 
the abdomen using a vacuum-assisted closure therapy in a damage- 
control manner. The second look was done 54 h later with reconstruc-
tion in a Roux-en-Y way. Histopathology of the GJ-resection demon-
strated ischemic transformation as well as acute, chronic inflammation 
of the anastomosis and again no signs of malignancy. Antibiotic therapy 
was continued for ten days after surgery, and the patient was transferred 
in a good general state of health to a rehabilitation clinic on day twelve. 
Three days after discharge from the rehabilitation center, the patient 
presented to our ED with a 12-hour history of vomiting and slight 
epigastric pain. Tenderness on palpation of the left hemiabdomen was 
noted with a discrete increase of CRP (10 mg/L). CT scan yielded an 
edematous thickening of the jejunal wall just distally to the GJA after 
RYGB without any free liquid or air. The patient was admitted to our 
ward for monitoring. The gastroscopy demonstrated multiple fibrinous 
defects (marginal ulcer) of the GJA as well as punctiform ischemic le-
sions of the jejunum just distally to the GJA (Fig. 2). Histopathology 
revealed active focal erosive inflammation of the lamina propria. Anti-
coagulation with intravenously heparin 15′000 IE per 24 h was given 
with suspected underlying ischemic cause for the recurrent complaints. 
Duplex sonography was performed by an angiologist where no relevant 
stenosis of the mesenteric blood vessels was found. In further medical 
history, the patient reported using an over-the-counter (OTC) 
xylometazoline-based (alpha-adrenergic sympathomimetic) nasal spray 
>15–20 blows/day (recommended maximum three blows/d for max. 7 
days) for nasal congestion. Timely coherence of recurrent abdominal 
complaints and intestinal perforation with increased xylometazoline use 
was found. The patient was advised to cease the use of alpha-adrenergic 
sympathomimetic nasal spray and smoking. She was discharged home 
on day five. 
Table 1 
Timetable, weight progression and interventions.   










Lap. sleeve gastrectomy     
13th July 
2017 
OPC  88.5  34.1 29.8% 61.3% 
21st June 
2018 
OPC  99  38.2   
26th June 
2018 
Lap. switch to omega 
loop     
02nd August 
2018 
OPC  91  35.1 27.8% 57.2% 
24th August 
2018 
Lap. suture of perforated 




gastroenteritis     
09th October 
2018 
Gastroscopy     
17th October 
2018 




OPC  85  32.8 32.5% 67.0% 
28th January 
2019 
Gastroscopy     
30th January 
2019 
Lactulose breath test     
07th August 
2019 
OPC  85  32.8 32.5% 67.0% 
28th August 
2019 













2nd look, RYGB     
08th 
February 
2021   
116  44.8 7.9% 16.3% 
18th 
February 
2021   





enteritis     
14th March 
2021 
Gastroscopy     
15th March 
2021   
102  39.4 19.0% 39.2% 
07th April 
2021 
Gastroscopy     
26th May 
2021 
Gastroscopy     
Abbreviations: Δ, delta; BMI, body mass index; %EWL, percentage of excess 
weight loss; GJA, gastro-jejunal anastomosis; Lap., laparoscopic; OPC, outpa-
tient clinic; RYGB, Roux-Y gastric bypass; %TWL, percentage of total weight 
loss. 
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Control gastroscopy two weeks after discharge documented a partial 
and at six weeks a complete resolution of the ischemic lesions. 
3. Discussion and conclusion 
To our knowledge, we present the first case of a 3.5 years follow-up 
period of a bariatric surgical intervention with recurrent complications 
(Clavien-Dindo Classification IIIb) most likely caused by an OTC nasal 
spray abuse, which has been reported according to the SCARE 2020 
Guidelines [10]. 
In this case, the first onset of perforation of anastomosis occurred two 
months after LOL-GB leading to revisional surgery. Retrospectively, the 
acute gastroenteritis approximately 1.5 months after surgery was most 
likely a less severe case of ischemia leading to admission to our clinic. In 
the following months, recurrent, less intense symptoms occurred, and 
several different diagnostically interventions were performed. Two and 
a half years after LOL-GB, perforation of the GJA necessitated the switch 
into RYGB in a two-staged damage control manner. 
Complication occurrence, adequate diagnostics as well as treatment 
modalities are ongoing topics of research interest. In a single-surgeon 
experience in the US, marginal ulcers (MU) occurred in 5.3% (122/ 
2282) of which 68% (83/122) were successfully treated without sur-
gery, whereas only one case (0.8%, 1/122) suffered from perforation 
[7]. The authors argued that the incidence (0.6%–16.0%) remains likely 
underestimated as symptoms of MU are variable and might be 
confounded with complaints of overeating [7]. Moreover, the etiology of 
MU incl. Perforation remains a matter of debate. 
Cervin et al. were able to demonstrate a decreased blood flow in the 
nasal septal mucosal tissue in humans 20 min after administration of 
xylometazoline by 61% [11]. In a review (2018), the use of intranasal 
vasoconstrictors has been discussed as a possible etiology of nasoseptal 
perforation [12]. In rats, nasal application of oxymetazoline has shown 
Fig. 1. Computed tomography scans, demonstrating perforation of gastrojejunal anastomosis with free air and liquid in horizontal, coronal and sagittal views. White 






Fig. 2. Gastroscopy images demonstrating multiple punctiform ischemic lesions (left) and marginal ulcer at gastrojejunal anastomosis (right; highlighted by the 
black stealth arrow). 
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significant systemic (rats' tail tissue) ischemic changes, necrosis, and 
ulceration accompanied by a possible trend of arterial thrombosis [13]. 
Preclinical data displays evidence of active metabolites of oxymetazo-
line in human, rat, and rabbit liver tissue [14]. However, the authors 
argued that safety concerns of systemic changes and toxicity are unlikely 
due to the short application period and lower dosages [14]. In literature, 
case reports or minor case series report stroke and non-ST-elevation 
myocardial infarction in use of nasal oxymetazoline and acute 
ischemia of the hand as a consequence of intra-arterial oxymetazoline 
injection, displaying rare systemic effects and resulting complications in 
oxymetazoline use [15–17]. 
Currently, as data is sparse, no recommendations are available on 
diagnostics and treatment for recurrent MU. Derived from the presented 
case, we advocate the evaluation of drug abuse, including OTC medi-
cations - which patients might not report - on a daily-based medical 
history, as well as possible medical interactions leading to a reduced 
blood perfusion as a cause for marginal ulcers and anastomosis perfo-
ration, especially in late and recurrent cases. 
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